The Clinically Tested Gardos Channel Inhibitor Senicapoc Exhibits Antimalarial Activity

Senicapoc, a Gardos channel inhibitor, prevented erythrocyte dehydration in clinical trials of patients with sickle cell disease. We tested the hypothesis that senicapoc-induced blockade of the Gardos channel inhibits Plasmodium growth. Senicapoc inhibited in vitro growth of human and primate plasmo...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Antimicrob Agents Chemother
Hlavní autoři: Tubman, Venée N., Mejia, Pedro, Shmukler, Boris E., Bei, Amy K., Alper, Seth L., Mitchell, James R., Brugnara, Carlo, Duraisingh, Manoj T.
Médium: Artigo
Jazyk:Inglês
Vydáno: American Society for Microbiology 2015
Témata:
Clinical Therapeutics
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC4704178/
https://ncbi.nlm.nih.gov/pubmed/26459896
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1128/AAC.01668-15
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky